Evidence map›Paper›PMID 28705932›Full record

ArticleThe Journal of biological chemistry2017

Use of a neutralizing antibody helps identify structural features critical for binding of

Heather K Kroh, Ramyavardhanee Chandrasekaran, Kim Rosenthal, Rob Woods, Xiaofang Jin, Melanie D Ohi, Andrew C Nyborg, G Jonah Rainey, Paul Warrener, Benjamin W Spiller and 1 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Mouse monoclonal antibodies againstInfection and immunity · 2025
    Article
  2. Rapid discrimination between clinicalFrontiers in microbiology · 2024
    Article
  3. Article
  4. Structure and conformational dynamics ofLife science alliance · 2022
    Article
  5. Review
  6. Review
  7. Article
  8. Neutralizing epitopes onFrontiers in immunology · 2022
    Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Heather K KrohFrom the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2363.
Ramyavardhanee ChandrasekaranFrom the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2363.
Kim RosenthalMedImmune LLC, Gaithersburg, Maryland 20878-2204.
Rob WoodsMedImmune LLC, Gaithersburg, Maryland 20878-2204.
Xiaofang JinMedImmune LLC, Gaithersburg, Maryland 20878-2204.
Melanie D Ohithe Department of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee 37232-8240.
Andrew C NyborgMedImmune LLC, Gaithersburg, Maryland 20878-2204.
G Jonah RaineyMedImmune LLC, Gaithersburg, Maryland 20878-2204.
Paul WarrenerMedImmune LLC, Gaithersburg, Maryland 20878-2204.
Benjamin W SpillerFrom the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2363, benjamin.spiller@vanderbilt.edu.
D Borden LacyFrom the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2363, borden.lacy@vanderbilt.edu.
Vanderbilt University · USVanderbilt University Medical Center · USVA Tennessee Valley Healthcare System · US

Funding

Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Structural mechanisms of Clostridium difficile pathogenesisR01AI095755 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LACY, DANA BORDEN · 2011 to 2020
$3.9M
Structural Mechanisms of Clostridioides difficile pathogenesisR37AI095755 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Dana Borden Lacy · 2021 to 2026
$3.2M
CopN mechanism as a key to understanding Type Three Secretion in bacteriaR01AI108778 · NIAID · VANDERBILT UNIVERSITY · PI SPILLER, BENJAMIN W · 2014 to 2018
$2.0M
Crystallographic AutomationS10RR026915 · NCRR · VANDERBILT UNIVERSITY · PI IVERSON, T M · 2010 to 2010
$490k
The role of toxins in Clostridium difficile infection pathogenesisI01BX002943 · VA · VETERANS HEALTH ADMINISTRATION · PI LACY, DANA BORDEN · 2016 to 2025
–
BLRD VA I01 BX002943NCRR NIH HHS S10 RR026915NIAID NIH HHS R01 AI095755NIAID NIH HHS R01 AI108778NIAID NIH HHS R37 AI095755NIDDK NIH HHS P30 DK058404
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Models, MolecularAmino Acid SequenceAnti-Bacterial AgentsAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingBacterial ProteinsBacterial ToxinsBinding Sites, AntibodyCaco-2 CellsClostridioides difficileConserved SequenceCrystallography, X-RayEnterocytesEnterotoxinsEpitope MappingGlucosyltransferasesAnti-Bacterial AgentsAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingBacterial ProteinsBacterial ToxinsEnterotoxinsGlucosyltransferasesImmunoglobulin Fab FragmentsPeptide FragmentsRecombinant ProteinstcdA protein, Clostridium difficilebacterial toxincell surface receptorClostridium difficilecrystal structureelectron microscopy (EM)monoclonal antibodySEC-MALS

Identifiers

PMID28705932
PMCPMC5582835
OpenAlexW2734704033

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.